The Reduce trial is designed to study the effectiveness of Paradise Ultrasound Transcatheter Renal Denervation system for treating resistant hypertension.

Results of the study will be presented on 17 May 2012 by principal investigator Thomas A. Mabin.

ReCor Medical president and CEO Mano Iyer said Paradise system is designed to provide a minimally invasive ultrasound therapy to resistant hypertension patients to help reduce their blood pressure.

"In the REDUCE study, we have been able to show that our novel PARADISE system is capable of safely and quickly denervating patients, resulting in sustained blood pressure reductions out to 6 months," Iyer added.

"We look forward to Dr. Mabin’s reporting of the current results of our REDUCE pilot clinical trial at PCR as we move forward with our launch of our PARADISE system in Europe."